- Job Seekers
- About UCB US
- R & D
UCB medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their therapy area.
Cimzia®(certolizumab pegol) is indicated in the U.S. for the treatment of adults patients suffering from moderately to severely active rheumatoid arthritis.
Cimzia®(certolizumab pegol) is also indicated in the U.S. for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Consult www.cimzia.com for full prescribing information.
Vimpat®(lacosamide) C-Ⅴ tablets and oral solution are indicated for adjunctive therapy in the treatment of partial-onset seizures in patients 17 years of age and older. Vimpat injection is indicated as short-term replacement when oral administration is not feasible in these patients. (Consult www.vimpat.com for full prescribing information.)
Neupro®(Rotigotine Transdermal System) is indicated in the U.S. for the treatment of signs and symptoms of idiopathic Parkinson's disease.
Neupro® (Rotigotine Transdermal System) is also indicated in the U.S. for the treatment of moderate-to-severe primary Restless Legs Syndrome. Consult www.neupro.com for full prescribing information.
Keppra XR®(levetiracetam) extended-release tablets are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.
Consult www.keppraXR.com for full prescribing information for Keppra XR and Keppra®.
Metadate CD®(methylphenidate HCl, USP) Extended Release capsules, CII are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Click here for full prescribing information.
Tussionex® Pennkinetic® (hydrocodone polistirex and chlorpheniramine polistirex) Extended-Release Suspension, CIII is indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older. Click here for full prescribing information.
Cimzia®, Keppra XR®, Keppra®, Neupro®, Metadate CD® and Tussionex® Pennkinetic® are trademarks of the UCB Group of Companies.
Vimpat® is a registered trademark under license from Harris FRC Corporation.
For additional information on other products not listed here, contact UCB Medical Information at +1.877.822.9493.